Study funded by ADDF finds dopamine therapy improves cognitive function in Alzheimer’s

NEW YORK, NY (July 15, 2020) – A study supported by the Alzheimer’s Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the brain, improves cognitive function in patients with mild-to-moderate Alzheimer’s disease. While rotigotine did not show a significant…

Details

Analysis of immune responses in COVID-19 patients identifies defining features of severe disease

An analysis of immune responses in 42 COVID-19 patients, both infected and recovered, identified immune signatures that distinguish severe COVID-19 cases. Notably, the analysis features insights not only into adaptive immune cell responses, but also those of innate immune cells responding to the virus. The findings will inform development of COVID-19 therapeutics. As the global…

Details

Detailed study of immune responses in COVID-19 patients reveals distinct ‘immunotypes’

Expanding on observations made in smaller patient cohorts, researchers studying immune responses of 125 hospitalized COVID-19 patients identified distinct immune profiles — “Immunotypes” — and showed how these signatures correlated with disease severity. “By localizing patients on an immune topology map,” Divij Mathew and colleagues say, “we can begin to infer which types of therapeutic…

Details